ArticleVeterinary research2025
Annexin A2 facilitates porcine circovirus type 2 infection by mediating viral attachment to host cells and interacting with the capsid protein.
Article in Veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrative bioinformatics and experimental analysis identify S100A10 as a diagnostic and prognostic biomarker in pancreatic adenocarcinoma.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Porcine circovirus type 2 (PCV2) causes substantial economic losses globally. Although glycosaminoglycans (GAGs) have been identified as the general cell receptors responsible for PCV2 binding and subsequent cell infection, other critical protein(s) may also be involved. Our objective was to explore key host proteins that mediate PCV2 infection. The host protein annexin A2 (ANXA2) was observed to interact with PCV2 virus-like particles (VLPs) through immunoprecipitation (IP) and liquid chromatography‒tandem mass spectrometry (LC‒MS/MS) experiments. Furthermore, knockdown of ANXA2 or the inhibitor A2ti-1 significantly reduced PCV2 replication in host cells. Notably, the addition of ANXA2-specific antibodies to cell culture or the preincubation of PCV2 with recombinant ANXA2 significantly reduced viral infection, primarily by weakening viral attachment to cells. Confocal microscopy further confirmed the colocalization of PCV2 Cap with endogenous ANXA2 in infected cells, and in vitro GST pull-down assays also demonstrated a direct interaction between these two proteins, confirming the role of ANXA2 as an attachment factor for PCV2 cellular entry. In addition, molecular docking revealed that an interface and multiple residues between PCV2 Cap and ANXA2 were involved in the interaction, which was also verified by truncation assays. In conclusion, ANXA2 on the cell surface may function as an attachment site, promoting viral binding and increasing PCV2 infectivity through interactions with Cap. These findings provide novel insights into the molecular mechanisms of PCV2 infection and new molecular targets for the development of vaccines and therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.